Peng Y, Butt YM, Chen B, Zhang X, Tang P. Update on immunohistochemical analysis in breast lesions. Arch Pathol Lab Med. 2017;141(8):1033–51.
Rampurwala MM, Rocque GB, Burkard ME. Update on adjuvant chemotherapy for early breast cancer. Breast Cancer. 2014;8:125–33.
Nabholtz J-MA, Reese DM, Lindsay M-A, Riva A. Docetaxel in the treatment of breast cancer: An update on recent studies. Semin Oncol. 2002;29(3):28–34.
Fisher B, Jeong J-H, Anderson S, Wolmark N. Treatment of axillary lymph node–negative, estrogen receptor–negative breast cancer: Updated findings from national surgical adjuvant breast and bowel project clinical trials. J Natl Cancer Inst. 2004;96(24):1823–31.
Kaufman PA. Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer. Semin Oncol. 1999;26:39–46.
Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin Cardiomyopathy. Cardiology. 2010;115(2):155–62.
Patel AG, Kaufmann SH. How does doxorubicin work? eLife. 2012;1
Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57:727–41.
Denard B, Lee C, Ye J. Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1. eLife Sci. 2012;1 https://doi.org/10.7554/eLife.00090.
Denard B, Seemann J, Chen Q, Gay A, Huang H, Chen Y, Ye J. The membrane-bound transcription factor CREB3L1 is activated in response to virus infection to inhibit proliferation of virus-infected cells. Cell Host Microbe. 2011;10:65–74.
Sivanand S, Peña-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A, Yamasaki T, McBride DJ, Gillen J, Wolff NC, et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med. 2012;4(137):137ra175.
Denard B, Pavia-Jimenez A, Chen W, Williams NS, Naina H, Collins R, Brugarolas J, Ye J. Identification of CREB3L1 as a biomarker predicting doxorubicin treatment outcome. PLoS ONE. 2015;10(6):e0129233.
Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review. Diagn Pathol. 2014;9:221.
Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, et al. Measurement of Residual Breast Cancer Burden to predict survival after neoadjuvant chemotherapy. J clin Oncol. 2007;25(28):4414–22.
Han JS, Cao D, Molberg KH, Sarode VR, Rao R, Sutton LM, Peng Y. Hormone receptor status rather than HER2 status is significantly associated with increased Ki-67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki-67 but not p53 Is significantly associated with axillary nodal metastasis in triple-negative and high-grade non–triple-negative breast carcinomas. Am J Clin Pathol. 2011;135(2):230–7.
Whitley E, Ball J. Statistics review 4: Sample size calculations. Crit Care. 2002;6(4):335–41.
Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–81.
Chen Q, Denard B, Huang H, Ye J. Epigenetic silencing of antiviral genes renders clones of Huh-7 cells permissive for Hepatitis C virus replication. J Virol. 2013;87(1):659–65.
Rose M, Schubert C, Dierichs L, Gaisa NT, Heer M, Heidenreich A, Knüchel R, Dahl E. OASIS/CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro. Epigenetics. 2014;9(12):1626–40.
Steenbergen RDM, Ongenaert M, Snellenberg S, Trooskens G, van der Meide WF, Pandey D, Bloushtain-Qimron N, Polyak K, Meijer CJLM, Snijders PJF, et al. Methylation-specific digital karyotyping of HPV16E6E7-expressing human keratinocytes identifies novel methylation events in cervical carcinogenesis. J Pathol. 2013;231(1):53–62.
Ward AK, Mellor P, Smith SE, Kendall S, Just NA, Vizeacoumar FS, Sarker S, Phillips Z, Alvi R, Saxena A, et al. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers. Breast Cancer Res. 2016;18:12.
Sato T, Issa J-PJ, Kropf P. DNA hypomethylating drugs in cancer therapy. Cold Spring Harb Perspect Med. 2017;7(5):a026948. https://doi.org/10.1101/cshperspect.a026948.
Khan GN, Kim EJ, Shin TS, Lee SH. Azacytidine-induced chemosensitivity to doxorubicin in human breast cancer MCF7 Cells. Anticancer Res. 2017;37(5):2355–64.